- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Boston Scientific has positive Farapulse, Farapoint data | ||
| Do | Medtronic signs distro deal to bring Dragonfly Endoscopy tech to U.S. | ||
| Do | Surgical Robotics Special Report | ||
| Do | CorWave progresses toward first-in-human heart pump trials | ||
| Do | MassDevice's Orthopedic Device Companies Special Report | ||
| Do | Integer to promote COO to corner office after CEO retires | ||
| Do | Anumana expands AI cardiac care platform with support from Boston Scientific | ||
| Do | Medtronic submits interoperable insulin pump to FDA to advance collaboration with Abbott | ||
| Do | Onward takes steps to improve U.S. investor access | ||
| Do | Bausch + Lomb is returning recalled intraocular lenses to the market | ||
| Do | Neuralink reportedly expects to raise $500M at $8.5B valuation | ||
| Mi | ResMed posts Street-beating Q3 | ||
| Mi | Edwards posts Street-beating Q1 results, ups 2025 sales guidance | ||
| Mi | Data backs Boston Scientific drug-eluting stent | ||
| Mi | Cook Medical, Mendaera collab on handheld robotics for needle-based interventions | ||
| Mi | Dr. Kolaleh Eskandanian joins Compremium's C-suite to lead new division | ||
| Mi | Imricor completes first-in-human ventricular ablation with MRI | ||
| Mi | NeuroOne completes FDA submission for nerve ablation tech to treat facial pain | ||
| Mi | Artedrone moves forward on autonomous micro-robot | ||
| Mi | CereVasc wins FDA breakthrough designation for eShunt in pediatric patients | ||
| Mi | Epiminder wins FDA de novo nod for implantable continuous EEG monitor | ||
| Mi | BD launches bioabsorbable mesh for hernia repair following FDA nod | ||
| Mi | Boston Scientific stock rises on Street-beating Q1, CFO to retire | ||
| Di | Intuitive stock falls despite Q1 beat as Trump's tariffs dampen forecast | ||
| Di | R3 Vascular reports first patient treated in next-gen drug-eluting scaffold study |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
